Organogenesis (NASDAQ:ORGO) stock rallied 17% post-market on Thursday after the company released a Q4 earnings report and guidance that topped Street expectations. The biotech company reported a Q4 ...

At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for ...

A negotiation for a tax stabilization agreement (TSA) between Smithfield and the biomedical company Organogenesis may be off to an unstable start, but the town and company seem ...

Rhumbline Advisers grew its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO – Free Report) by 7.1% during the 4th ...

Organogenesis Holdings shares soared after the company reported a profit in the fourth-quarter, while analysts had forecast a loss, and gave an upbeat outlook for the current year. Shares were ...

In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report), with a ...

Fourth Quarter 2024 Financial Results Summary: Net revenue from Advanced Wound Care products of $118.6 million, an increase of 27% from the fourth quarter of 2023. Net revenue from Surgical & Sports ...

Organogenesis Holdings Inc (ORGO) reports a 27% revenue increase and outlines future growth strategies amid market challenges.

CANTON, Mass. (AP) — CANTON, Mass. (AP) — Organogenesis Holdings Inc. (ORGO) on Thursday reported profit of $7.7 million in its fourth quarter. On a per-share basis, the Canton, Massachusetts ...

Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2024 earnings conference call for Organogenesis Holdings, Inc. At this time, all participants have been placed in listen-only mode.